Clinical Trials Logo
  1. Home
  2. Small Cell Lung Cancer (SCLC)
  3. NCT04727853

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer (SCLC) Clinical Trial

Official title:
A Multicenter, Open-label, Single-arm Phase 2 Study of Irinotecan Liposome Injection in Patients With Small Cell Lung Cancer (SCLC) Who Have Progressed After Platinum-based First-line Therapy

Clinical Trial Summary

This study is a multicenter, open-label, single-arm phase 2 study of irinotecan liposome injection in patients with small cell lung cancer (SCLC) who have progressed after platinum-based first-line therapy. Subjects will receive irinotecan liposome injection until progression or unacceptable toxicity.

Clinical Trial Description

Patients with small cell lung cancer who have progressed after platinum-based first-line therapy will be enrolled in this study. Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, over 90 min on Days 1 of every 14-day cycle until progression or unacceptable toxicity. Imaging assessments will be conducted every three cycles to evaluate the preliminary efficacy of irinotecan liposome injection as second-line regimen in patients with SCLC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04727853
Study type Interventional
Source CSPC Ouyi Pharmaceutical Co., Ltd.
Contact Xuekun Yao, Director
Phone +8631169085937
Email yaoxuekun@mail.ecspc.com
Status Not yet recruiting
Phase Phase 2
Start date March 1, 2021
Completion date June 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05652686 - A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Phase 1/Phase 2
Recruiting NCT05027100 - Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC N/A
Active, not recruiting NCT03708328 - A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT05158491 - Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC Phase 1/Phase 2
Recruiting NCT05740566 - Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Phase 3
Completed NCT04285866 - Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
Completed NCT03066778 - A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Phase 3
Withdrawn NCT02030184 - Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas Phase 1/Phase 2
Completed NCT03538028 - A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Phase 1
Withdrawn NCT01210131 - Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC) N/A
Terminated NCT01904253 - A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy Phase 2
Terminated NCT02934503 - Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) Phase 2
Completed NCT02580994 - Pembrolizumab in Untreated Extensive SCLC Phase 2
Completed NCT03811652 - A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT02628067 - Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Phase 2
Active, not recruiting NCT02769832 - Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer Phase 2
Completed NCT02069158 - Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor Phase 1
Recruiting NCT03460977 - PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Phase 1